

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-38. (canceled)

39. (new) A preparation suitable for the prevention and/or treatment of dementia syndromes, cognitive degeneration or hearing loss, comprising the following fractions:

a) long chain polyunsaturated fatty acids comprising at least one Ω -3 fatty acid selected from the group consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), at least one Ω -6 fatty acid selected from the group consisting of dihomogammalinolenic acid (DHGLA) and arachidonic acid (AA), and at least one member selected from the group consisting of linoleic acid and α -linolenic acid; wherein the ratio of the total amount of EPA + DHA + DHGLA + AA to the total amount of linoleic acid and α -linolenic acid is above 0.4:1; and wherein the weight ratio of the total amount of EPA + DHA to the total amount of DHGLA + AA is in the range from 2.5:1 to 5.5:1;

b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and

c) at least one factor in methionine metabolism, selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.

40. (new) The preparation according to claim 39, further comprising d), wherein d) comprises at least one of citrates or citric acid.

41. (new) The preparation according to claim 39, further comprising e), wherein e) comprises huperzine A.

42. (new) The preparation according to claim 39, wherein the Ω -3 fatty acid is EPA, and the Ω -6 fatty acid is DHGLA.

43. (new) The preparation according to claim 39, wherein fraction c) comprises folic acid and vitamin B6.

44. (new) The preparation according to claim 39, wherein fraction c) further comprises at least one member selected from the class consisting of S-adenosylmethionine, choline, betaine and copper.

45. (new) The preparation according to claim 44, wherein fraction c) further comprises zinc and copper and wherein the weight ratio of zinc to copper is between 5:1 and 12:1.

46. (new) The preparation according to claim 39, which further contains a fraction f) consisting of at least one member selected from the group consisting of carnitine, vitamin B1, vitamin B5 and coenzyme Q10.

47. (new) The preparation according to claim 39, which further contains a fraction g) consisting of at least one antioxidant selected from the group consisting of vitamin C, vitamin E, lipoic acid, selenium salts and carotenoids.

48. (new) The preparation according to claim 39, which further contains a fraction h) consisting of an extract of ginkgo biloba.

49. (new) The preparation according to claim 39, which comprises per daily dose:

at least 120 mg of long chain polyunsaturated fatty acids;

at least 200 mg phospholipids;

at least 200 µg folic acid; and

at least 500 mg citrate.

50. (new) The preparation according to claim 39, which comprises per daily dose:

at least 20 mg eicosapentaenoic acid;

at least 50 mg docosahexaenoic acid;

at least 50 mg arachidonic acid;

at least 200 mg phospholipids;

at least 200 µg folic acid;

at least 100 mg magnesium;

at least 5 mg zinc;

at least 2 mg vitamin B6;

at least 2 µg vitamin B12; and

at least 1.0 g citrate.

51. (new) The preparation according to claim 39, in the form of a nutritional supplement.

52. (new) A preparation suitable for the prevention and/or treatment of dementia syndromes, cognitive degeneration or hearing loss, comprising the following fractions:

a) long chain polyunsaturated fatty acids comprising at least one member selected from the group consisting of eicosapentaenoic acid (EPA), docosaheptaenoic acid (DHA), dihomogammalinolenic acid (DHGLA) and arachidonic acid (AA), and at least one member selected from the group consisting of linoleic acid and α -linolenic acid; and wherein the ratio of the total amount of EPA + DHA + DHGLA + AA to the total amount of linoleic acid and α -linolenic acid is above 0.4:1;

b) phospholipids comprising phosphatidylcholine and phosphatidylethanolamine and at least one of phosphatidylserine and phosphatidylinositol, wherein the weight ratio of phosphatidylcholine and phosphatidylethanolamine to phosphatidylserine and phosphatidylinositol is in the range from 0.5:1 to 20:1; and

c) at least one factor in methionine metabolism, selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.

53. (new) The preparation according to claim 52, further comprising d) at least one of citrates or citric acid.

54. (new) The preparation according to claim 52, wherein fraction c) comprises at least folic acid and vitamin B6.

55. (new) The preparation according to claim 52, wherein a) comprises at least one of EPA and DHA and at least one of DHGLA and AA.